Moreover, ACE2 improves pathological angiogenesis and BBB damage in AD models by inhibiting the NF-κB/VEGF/VEGFR2 pathway, making it a potential therapeutic target for endothelial dysfunction in AD [79]. Here, VEGFA is linked to Alzheimer disease.